Krishnamurthy & Co (K Law) advised Biocon Biologics India when Tata Capital acquired a 0.85% stake in it for ₹2.25 billion (US$30 million). Platinum Partners advised Tata Capital, which invested through Tata Capital Growth Fund II.
Biocon Biologics India is a subsidiary of Biocon, a listed biopharmaceuticals company.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
